Supreme Court Questions Huge Gap Between ₹2,700 PTR and ₹27,000 MRP of Cancer Drug

New Delhi: The Supreme Court has raised serious concerns over the pricing of life-saving cancer medicines in India after examining a case in which a cancer drug with a Price to Retailer (PTR) of around ₹2,700 carried a Maximum Retail Price (MRP) of ₹27,000.

The nearly ten-fold difference between the two figures prompted the Court to question how such a substantial pricing gap could exist for a medicine required by patients battling a serious disease.

The issue has once again brought India's pharmaceutical pricing system, trade margins and the affordability of cancer treatment under scrutiny.

Supreme Court Raises Questions Over Cancer Drug Pricing

During the proceedings, the Supreme Court expressed strong concern about unusually large differences between the price at which certain medicines reach retailers and the MRP printed on their packaging.

The Court reportedly used strong terms including “extortion” and “daylight dacoity” while discussing excessive margins and questioned whether the existing regulatory framework was adequately protecting patients.

The ₹2,700 and ₹27,000 figures, however, need to be understood correctly.

The ₹2,700 figure represents the Price to Retailer (PTR) cited before the Court, while ₹27,000 represents the MRP. Therefore, it would be misleading to simply claim that a medicine “costing ₹2,700 was sold to every patient for ₹27,000.”

The central concern is the extraordinary gap between the two pricing points.

Cancer Treatment Can Put Families Under Financial Pressure

Cancer treatment can involve prolonged expenditure on medicines, hospitalisation, diagnostic tests and follow-up care.

For patients who require expensive medicines regularly, even relatively small differences in prices can significantly affect the overall cost of treatment. A several-fold difference between the retailer price and printed MRP therefore raises important questions about transparency and trade margins.

The Supreme Court's observations have renewed attention on whether patients are receiving the benefits of lower procurement prices or whether unusually large margins remain embedded in the medicine supply chain.

How Does India Control Medicine Prices?

Medicine prices in India are regulated primarily under the Drugs (Prices Control) Order, 2013 (DPCO), with the National Pharmaceutical Pricing Authority (NPPA) playing the key regulatory role.

For medicines covered by price-control provisions, ceiling prices are fixed and manufacturers cannot legally charge above the applicable permitted price.

However, not every medicine sold in India falls under the same form of direct price control.

A substantial portion of India's pharmaceutical market consists of non-scheduled formulations, where manufacturers have greater flexibility in determining initial prices, subject to applicable pricing regulations.

Government and parliamentary material indicates that approximately 80–82% of the pharmaceutical market consists of non-scheduled formulations.

Government Has Previously Intervened in Cancer Drug Margins

Concerns surrounding cancer-drug affordability are not new.

The NPPA has previously introduced Trade Margin Rationalisation for selected non-scheduled anti-cancer medicines in an effort to reduce excessive margins between the price charged by manufacturers and the final price paid by patients.

The intervention resulted in substantial price reductions across hundreds of cancer medicine brands, with particularly large reductions recorded in some cases.

Government information has also stated that ceiling prices for 131 anti-cancer drugs and formulations were in effect as of March 2026, with price-control measures estimated to generate significant annual savings for patients.

Fact Check: Viral ₹52.81 Crore Sales Claim Needs Caution

Another claim circulating with the Supreme Court story states that annual sales of anti-cancer medicines in India amount to only ₹52.81 crore, allegedly according to a government pharmaceutical report.

This figure should not be treated as established fact without a verifiable primary source.

Available government pharmaceutical data have reported anti-neoplastic medicine sales running into thousands of crores of rupees, substantially higher than ₹52.81 crore.

The ₹52.81 crore claim therefore appears to be either incorrectly quoted, taken from a different dataset or presented without the necessary context.

What Is Actually Verified?

The key claim concerning the Supreme Court proceedings is substantially correct: the Court questioned a case involving a cancer medicine with a PTR of approximately ₹2,700 and an MRP of ₹27,000.

The large difference does not automatically prove that every patient purchased the medicine at ₹27,000, but it raises serious questions about how such margins are created and how much of the benefit of lower procurement prices ultimately reaches patients.

The controversy has once again highlighted a larger challenge facing India's healthcare system—ensuring that life-saving medicines remain affordable while maintaining transparency throughout the pharmaceutical supply chain.

For permission to reuse our original reporting or images, contact The Jalandhar Times.